de Juan Ferré, AÁlvarez Álvarez, RCasado Herráez, ACruz Jurado, JEstival González, AMartín-Broto, JMartínez Marín, VMoreno Vega, ASebio García, AValverde Morales, C2023-02-092023-02-092021-01-06http://hdl.handle.net/10668/16929Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/GuidelinesSarcomaSoft-tissue tumorsUncommon tumorsAnthracyclinesAntineoplastic AgentsChecklistChemotherapy, AdjuvantDermatofibrosarcomaFemaleFibromatosis, AggressiveHumansMagnetic Resonance ImagingMaleMedical OncologyNeoadjuvant TherapyRadiotherapyRetroperitoneal NeoplasmsSarcomaSocieties, MedicalSoft Tissue NeoplasmsSolitary Fibrous TumorsSpainTomography, X-Ray ComputedUterine Neoplasmsresearch article33405052open access10.1007/s12094-020-02534-01699-3055PMC8057970https://link.springer.com/content/pdf/10.1007/s12094-020-02534-0.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057970/pdf